News Center

Company news

Media reports

24

2022-01

Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826

Suzhou, January 24, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("pyrilutamide") in China for the treatment of acne vulgaris.

Picture Name

07

2022-01

Kintor: Q4 2021 Business Update at A Glance

Q4 2021 Business Update at A Glance

Picture Name

02

2022-01

Kintor Pharma Announces First Patient Dosing of Phase III Clinical Trial of KX-826 (Pyrilutamide) for Treating Androgenic Alopecia Patients in China

Suzhou, January 2, 2022 - Kintor Pharmaceutical Limited, a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first dosing in its phase III clinical trial of KX-826 in China for the treatment of male androgenetic alopecia (AGA) patients on December 31, 2021.

Picture Name

27

2021-12

Kintor Pharma Provides Update on One of its Three Multi-Regional Phase 3 Trials of Proxalutamide for COVID-19

Suzhou, December 27, 2021 — Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today provided an update on its multi-regional study of proxalutamide for the treatment of COVID 19 infection (NCT04870606).

Picture Name

24

2021-11

Kintor Pharma Receives IND Clearance by NMPA for KX-826’s Pivotal Study to Treat Male Alopecia Patients

Suzhou, November 24, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the IND application for the pivotal study (phase III stage) of pyrilutamide (KX-826), a potential first-in-class drug developed by Kintor Pharma, for the treatment of male androgenetic alopecia (“AGA”) patients was cleared by the National Medical Products Administration (“NMPA”). KX-826 is the first androgen receptor (AR) antagonist which has entered the phase III clinical trial for AGA treatment in China and global.

Picture Name

12

2021-11

Kintor Pharma Announces Dosing of First Patient in Phase II Clinical Trial of KX-826 for the Treatment of Androgenic Alopecia Female Patients in China

Suzhou, November 12, 2021 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, today announced that the company has dosed the first patient in its phase II clinical trial of pyrilutamide ("KX-826") in China for the treatment of androgenetic alopecia (AGA) female patients.

Picture Name
< 1...111213...27 > proceed page

Kintor